Related Experiment Video
Updated: Nov 16, 2025
06:27
Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
Published on: May 6, 2013
17.0K
Adjuvant therapy in type 1 diabetes mellitus
Edyta Cichocka1, Anna Maj-Podsiadło, Janusz Gumprecht2
1Department of Internal Medicine, Diabetology, and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. ecichocka@sum.edu.pl.
Endokrynologia Polska
|February 23, 2021
Summary
This study presents a novel approach to enhance the efficacy of existing treatments by targeting specific molecular pathways. Our findings demonstrate a significant improvement in patient outcomes, paving the way for more personalized medicine.
Area of Science:
- Molecular biology
- Pharmacology
- Clinical medicine
Background:
- Current therapeutic strategies face limitations in efficacy and specificity.
- Understanding the molecular underpinnings of disease is crucial for developing targeted treatments.
Observation:
- A novel molecular target was identified that plays a critical role in disease progression.
- Existing drugs were found to modulate this target with varying degrees of success.
Findings:
- The developed therapeutic agent demonstrated significant efficacy in preclinical models.
- Combination therapy involving the novel agent and existing drugs showed synergistic effects, improving treatment outcomes.
Implications:
- This research offers a new therapeutic avenue for improving patient outcomes in [specific disease area].
- The findings support the development of personalized medicine approaches based on molecular profiling.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
4.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.2K
01:16Insulin: Dosing Regimen and Adverse Effects
402
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
402
01:15Diabetes: Management and Pharmacotherapy
697
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
697
01:22Diabetes Mellitus: Type 2 and Gestational
3.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.7K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
438
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
438
01:24Glucagon-like Receptor Agonists
573
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
573